Phyteau
Phyteau is a biotech spin-out from Cedars-Sinai Medical Center, CALTECH, and UCLA, focused on developing safe and effective therapeutics for diabetes, obesity, and metabolic conditions. Their innovative approach leverages a new class of incretin-based therapy to improve health outcomes at a lower cost, aiming to reverse metabolic diseases and improve quality of life.
Industries
biotechnology
diabetes
dietary-supplements
food-and-beverage
medical
nutraceutical
nutrition-654b
pharmaceutical
wellness
Nr. of Employees
small (1-50)
Products
Oral incretin-based therapeutic (weight loss and diabetes pill)
An orally administered therapeutic candidate designed to activate enteroendocrine hormone release to reduce postprandial glucose peaks and increase satiety while limiting systemic exposure.
Oral incretin-based therapeutic (weight loss and diabetes pill)
An orally administered therapeutic candidate designed to activate enteroendocrine hormone release to reduce postprandial glucose peaks and increase satiety while limiting systemic exposure.
Expertise Areas
- Metabolic disease therapeutics
- Incretin and enteroendocrine biology
- Oral drug delivery for gut-restricted action
- Translational research from academia to therapeutics
Key Technologies
- Enteroendocrine modulation
- Incretin-based therapeutic platforms
- Gut-restricted oral delivery
- Hormone release modulation (GLP-1, PYY, OXM, CCK)